Centre National De La Recherche Scientifique

Institut Gustave Roussy

National Institute of Health and Medical Research

Other

Institut Pasteur

National Institute for Agricultural Research

Université Paris—sud

University of Paris Sud XI

Bioalliance Pharma

Université Paris Sud-Paris Xi

Bioalliance Pharma Sa

Universite De Paris 11 - Paris Sud

Université Paris-Saclay

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Didier Desmaele

Patrick Couvreur

Thierry Martens

Michael Rivard

Jean D'Angelo

Angelo Paci

Fatima Zouhiri

Joachim Caron

Hervé Leh

Jean-Francois Mouscadet

Christian Auclair

Ruxandra Gref

Felix Augusto Rey

Stéphane Duquerroy

Jean-François Eleouet

Frédéric Subra

Anny Slama Schwok

Bogdan Tarus

Christina Sizun

Charles Skarbek

Fat'ma Zouhiri

Reddy Harivardhan Lakkireddy

Aurélie Mousnier

Catherine Dargemont

Sabine Bonnenfant

Jean-François Mouscadet

Christophe Benard

Michele Danet

Marc Le Bret

Marie Bayle

Laurence Jeanson

Khalid Mekouar

Fr&egrave;d&egrave;ric Subra

The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.

Antiviral agents directed against respiratory syncytial virus

The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.

Derivatives of oxazaphosphorines that are pre-activated, use and method of preparation

The present invention relates to novel derivatives of oxazaphosphorines, pharmaceutical compositions and therapeutic uses thereof, in particular for treating or preventing cancer.

Derivatives of oxazaphosphorines and therapeutic uses thereof

A complex formed of at least one molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or a derivative covalently bonded with at least one hydrocarbon radical with formula (A) as follows: wherein: &#x2022;-m 1=1, 2, 3, 4, 5 or 6; &#x2022;-m 2=0, 1, 2, 3, 4, 5 or 6; and represents the site of the bond with the molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or derivative. Formula (I) 

Vitamin C complexes

The present invention relates to a complex made up of at least one molecule of statin or a derivative thereof, covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one 2-methyl-buta-2-ene unit, to nanoparticles of such a complex, and to a method for preparing same, said complex and/or said nanoparticles optionally being in the form of a lyophilizate. The present invention also relates to a pharmaceutical composition including at least one complex and/or nanoparticles such as previously defined. The invention finally relates to said complex and/or to said nanoparticles for the treatment and/or prevention of hyperlipemia and hypercholesterolemia.

Statin nanoparticles

The invention relates to the use of 8-hydroxyquinoline 7-carboxylic acid derivatives in order to produce integrase-inhibiting medicaments, capable of blocking viral replication in the stages preceding integration, and if appropriate at the level of this integration stage, these medicaments being usable for the treatment of retroviral pathologies, in particular for the treatment of AIDS.

Use of quinoline derivatives with anti-integrase effect and applications thereof

The invention relates to derivatives corresponding to formula I: in which

Quinoline derivatives process of synthesis and medicaments containing these derivatives

The invention concerns quinoline derivatives of formula (I) in which: R , R and R , identical or different represent one or several substituents, themselves identical or different, in any position on the cycles, this or these substituents being selected among a &mdash;(CH ) &mdash;Y or &mdash;CH&boxH;CH&mdash;Y group, in which Y is halogen, &mdash;OH, &mdash;OR, &mdash;COH, &mdash;COR, &mdash;COOH, COOR, &mdash;COH, &mdash;COR, &mdash;CONH , &mdash;CON(R , R )&mdash;CH&boxH;NOH, &mdash;CO&mdash; &mdash;CH&boxH;NOH, &mdash;NH , &mdash;N(R , R ), &mdash;NO , &mdash;PO(OR) &mdash;SH , &mdash;SR, &mdash;SO R, &mdash;SO NHR, CN, or Z(R ) in which R is a C1-C8 alkyl, or aryl or a heterocyclic compound, R and R , identical or different are C1-C5 alkyl, an aryl or heterocyclic compound and n is nil or a whole number between 1 and 5 R can further represent a hydrogen, and when Y is &mdash;COOH or &mdash;COOR in R , Z, if it represents an aryl, comprises at least 3 substituents or the quinoline ring is trisubstituted; X is an ethylene double bond; a &mdash;(CH ) &mdash; group in which n is a whole number between 1 and 5: or a &mdash;CH(R &mdash;CH(R ) group, R and R , identical or different, representing a hydrogen, a halogen, hydroxy or epoxy; or a &mdash;(CH ) , &mdash;O&mdash;C&mdash;(CH ) &mdash;, &mdash;(CH ) , &mdash;C(O)&mdash;O&mdash;(CH ) , &mdash;(CH ) , &mdash;O&mdash;(CH ) &mdash;, (CH ) , &mdash;N(Q)&mdash;(CH ) &mdash;, or (CH ) , &mdash;S(O)&mdash;(CH ) &mdash;, group, in which n&equals;1 to 8, m&equals;0 to 8, t&equals;0, 1 or 2, and Q&equals;h, aryl or alkyl. The invention also concerns the pharmaceutically acceptable salts of these derivatives, the diastereoisomeric and the enantiomeric forms thereof. The invention is useful as medicines with HIV anti-integrase inhibiting effect.

Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereof

Growing community of inventors

Fresnes, France

Didier Desmaele